StreetAlpha.app
Home › Stocks › VCYT

Veracyte, Inc. (VCYT)

Healthcare
$25.13
▲ +0.36%
LAST CLOSE · NOV 20

Veracyte sells diagnostic tests, many for cancer, to physicians and healthcare providers from South San Francisco, California. It last closed at $25.13 on Nov 20, up 0.36% on the day. The next earnings report for VCYT is expected around Mon, Jan 11, 2027. For the quarter ended Sep 2026, VCYT reported EPS of $0.38 on revenue of $151.8M, with revenue up 15.1% from a year ago. Over its last 8 reports the stock moved an average of 19.7% the session after earnings. Over the last 12 months VCYT insiders bought $0 of stock on the open market and sold $19.2M, according to SEC Form 4 filings.

AI Auto Pilots
Is VCYT in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VCYT.

Key Stats

Last 12 months
Results
Revenue
$581.8M
+17.5% vs a year ago
Net income
$126.8M
+318.4% vs a year ago
EPS (diluted)
$1.54
+305.3% vs a year ago
Free cash flow
$161.9M
27.8% margin
Valuation
Market cap
$2.0B
80.7M shares
P/E
16.3
Price over 12 month EPS
Price to sales
3.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$199.8M
At Sep 30
Shareholder equity
$1.4B
Shares outstanding
80.7M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $219.5M$219.5MFY2021FY2022: $296.5M$296.5MFY2022FY2023: $361.1M$361.1MFY2023FY2024: $445.8M$445.8MFY2024FY2025: $517.1M$517.1MFY2025

From VCYT's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Jan 11
Estimated date · Time not announced
Reported EPS
$0.38
Quarter ended Sep 2026
Year ago EPS
$0.24
+58.3% on a GAAP basis
Revenue
$151.8M
+15.1% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: $0.06Dec '24Mar 2025: $0.09Mar '25Jun 2025: -$0.01Jun '25Sep 2025: $0.24Sep '25Dec 2025: $0.50Dec '25Mar 2026: $0.35Mar '26Jun 2026: $0.31Jun '26Sep 2026: $0.38Sep '26Latest $0.38
Revenue by quarter
Dec 2024: $118.6MDec '24Mar 2025: $114.5MMar '25Jun 2025: $130.2MJun '25Sep 2025: $131.9MSep '25Dec 2025: $140.6MDec '25Mar 2026: $139.1MMar '26Jun 2026: $150.3MJun '26Sep 2026: $151.8MSep '26Latest $151.8M
How VCYT moved after its last 8 reports
Average move the session after a report ±19.7%
Nov 4, 2026After the close−54.3%
Jul 30, 2026After the close−22.5%
May 5, 2026After the close+24.9%
Feb 25, 2026After the close+8.5%
Jan 12, 2026Time not announced+3.4%
Nov 4, 2025After the close+27.5%
Aug 6, 2025After the close+15.5%
May 7, 2025After the close+1.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VCYTStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VCYT
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VCYT

Technical Analysis

VCYT · as of the Nov 20 close · updated each morning
Downtrend, oversold

The stock is 39% below its 20 day and 61% below its 50 day average. It is 67% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 31), oversold. The nearest support is the Pivot at $25.09, and the nearest resistance the Pivot R1 at $25.64.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 11.3%/day
Key levels
$60.9152 week high+142.4%
$45.99Swing high (Sep 3)+83.0%
$44.86100 day average+78.5%
$42.08200 day average+67.4%
$40.4150 day average+60.8%
$34.9520 day average+39.1%
$25.64Pivot R1+2.0%
$25.13Last close
$25.09Pivot−0.2%
$24.57Pivot S1−2.2%
$23.27Swing low (Nov 16)−7.4%
$21.9152 week low−12.8%
Indicators
RSI (14)31.28Weak, oversold below 30Neutral
MACD-5.64Below its signal lineBearish
Stochastic10.8Near the bottom of its rangeOversold
ADX (14)41.6Strong downtrend
Williams %R-89.6Oversold below −80, overbought above −20Oversold
CCI (20)-53.7Oversold below −100, overbought above 100Neutral
Rate of change+4.0%Change over 10 sessionsBullish
ATR (14)$2.83Typical daily range, 11.3% of price
MA 10Above
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VCYT

What happened before

See how VCYT did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VCYT usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VCYT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2013.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VCYTHow many large options trades hit VCYT, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

VCYT Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲248 buying vs 147 selling
  • ▲Held by funds +6.8 pts
  • ▲Funds holding +11
  • ▼Superinvestors: 2 added, 3 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding384373+2.9%
In funds' top 1021+100.0%
Held by funds117.3%110.5%+6.8 pts
New / increased75 / 17377 / 128+21.0%
Reduced / sold out86 / 61122 / 41−9.8%
Put/call ratio0.910.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VCYT institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VCYT Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$19.2M31 sales · 11 insiders
94% of the selling was under pre-arranged trading plans.
2025-12 sold $2.5M2026-03 sold $3.2M2026-05 sold $1.9M2026-06 sold $8.2M2026-09 sold $1.3M2026-10 sold $1.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Oct 27Karin EasthamDirectorSale plan14,850$50.00$743K
Oct 27Jens HolsteinDirectorSale plan15,000$48.50$728K
Oct 19Muna BhanjiDirectorSale plan1,864$43.70$81K
Sep 21John LeiteGlobal Chief Commercial OffSale plan4,015$40.00$161K
Sep 14Jens HolsteinDirectorSale plan5,000$40.95$205K
Sep 4Phillip G. FebboChief Scientific & Med OfficerSale plan13,110$43.05$564K
Every insider buy and sale for VCYT over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VCYT insider trades →

From SEC Form 4 filings by VCYT's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VCYT is in one of them and how their past VCYT trades turned out.

VCYT in the AI portfolios
Loading…

VCYT News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VCYT in an article yet. Here's the latest on the wider market.

VCYT in the news

VCYT Congress Trades

All congress trades →
Trades, 12 months
3
Buys
2
67%
Sells
1
33%
People
1
Last filed Apr 7
Who traded VCYT · since 2019
Latest 5 filings of 15
$1K – $15KTraded Mar 3, 2026Filed Apr 7, 2026
$1K – $15KTraded Feb 18, 2026Filed Mar 9, 2026
Gilbert CisnerosSell (partial)
$1K – $15KTraded Nov 12, 2025Filed Dec 15, 2025
$1K – $15KTraded Jun 16, 2025Filed Jul 10, 2025
$1K – $15KTraded Oct 16, 2023Filed Nov 11, 2023
PersonTypeAmountTradedFiledDelay
Gilbert CisnerosD · CABuy$1K – $15KMar 3, 2026Apr 7, 202635 d
Gilbert CisnerosD · CABuy$1K – $15KFeb 18, 2026Mar 9, 202619 d
Gilbert CisnerosD · CASell (partial)$1K – $15KNov 12, 2025Dec 15, 202533 d
Gilbert CisnerosD · CABuy$1K – $15KJun 16, 2025Jul 10, 202524 d
Josh GottheimerD · NJBuy$1K – $15KOct 16, 2023Nov 11, 202326 d

From official House and Senate disclosure reports, filed up to 45 days after the trade and shown in dollar ranges. Not investment advice. Use limited by 5 U.S.C. 13107. About this data

About Veracyte

Veracyte is a diagnostic company based in South San Francisco, California. It develops and sells tests, many of them for cancer, that help physicians make decisions about patient care. Its best-known product is the Prosigna breast cancer test, which is available in international markets and runs on the nCounter Analysis System. The company also offers thyroid testing services and performs many of its tests in its own laboratories for physicians and healthcare providers.

Headquarters
South San Francisco, CA